Pharmacogenomic Testing: Assay Design, Validation & MolDX Guide

Clinical pharmacogenomic (PGx) testing identifies germline genetic variants that alter drug metabolism, transport, or receptor sensitivity, enabling clinicians to tailor medication selection and dosing to an individual patient's genetic profile. For high-complexity clinical laboratories, establishing a validated PGx test requires selecting an appropriate molecular technology, defining allele panels aligned with Association for Molecular Pathology (AMP) Tier 1 recommendations, resolving complex structural challenges like CYP2D6 copy-number variants and pseudogene interference, translating star-allele haplotypes into standard Clinical Pharmacogenetics Implementation Consortium (CPIC) metabolizer phenotypes, and satisfying stringent Medicare Local Coverage Determinations (LCDs) administered by the MolDX program.

Key takeaways

• Allele Selection Standards: Clinical assay panels must include consensus minimum alleles defined by the Association for Molecular Pathology (AMP) and College of American Pathologists (CAP), such as Tier 1 alleles for CYP2C19, CYP2D6, and CYP2C9, before expanding to Tier 2 exploratory targets.
• Structural Variant Challenges: Accurately characterizing CYP2D6 requires assay architectures that differentiate functional alleles from pseudogenes (CYP2D7, CYP2D8) and quantify copy-number variations (CNVs), including whole-gene deletions (*5), duplications, and hybrid rearrangements.
• Standardized Phenotype Calling: Laboratories should translate star-allele (*) diplotypes into functional metabolizer classifications using consensus CPIC and Dutch Pharmacogenetics Working Group (DPWG) guidelines, including the standardized CYP2D6 Activity Score system.
• Restrictive Payer Policies: Under Medicare MolDX LCDs (such as LCD L38294), unguided broad multi-gene panels are non-covered; reimbursement requires clinical indications for each gene tied to CPIC Level A recommendations or FDA drug label boxed warnings, alongside a registered DEX Z-Code and approved Technical Assessment.
• Bioinformatics and CDS Validation: In silico validation of Clinical Decision Support (CDS) translation engines and diplotype calling software is just as critical under CLIA/CAP as wet-bench analytical validation.

Assay Architecture: Technologies, Nomenclature, and Phenotype Translation

Developing a clinical PGx laboratory-developed test (LDT) begins with balancing throughput, turnaround time, variant spectrum, and capital requirements across molecular detection platforms.

Detection Platforms in Pharmacogenetics

Laboratories generally implement one of four primary detection strategies:

1. Targeted Real-Time PCR (TaqMan Allelic Discrimination): Fast and cost-effective for focused allele panels, but limited in multiplexing capacity and unable to detect uncharacterized or novel variants.
2. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry: High-throughput, multiplexed targeted genotyping (e.g., Agena MassARRAY) well-suited for mid-to-large variant panels, though structural variation and novel variant detection remain constrained.
3. Targeted Next-Generation Sequencing (NGS): Highly scalable for comprehensive panels and novel single-nucleotide variant (SNV) discovery; however, short-read NGS requires specialized bioinformatic pipelines and deep read-depth algorithms to resolve highly homologous pseudogenes and phase ambiguous haplotypes.
4. Long-Read Sequencing and Orthogonal CNV Assays: Technologies such as long-read sequencing (Pacific Biosciences, Oxford Nanopore) or multiplex ligation-dependent probe amplification (MLPA) and droplet digital PCR (ddPCR) provide direct phase resolution and definitive copy-number quantification across complex loci.

Star-Allele Nomenclature and PharmVar Standards

Unlike somatic oncology testing, which typically reports variants via HGVS notation, pharmacogenetics relies on the star-allele (*) nomenclature system maintained by the Pharmacogene Variation Consortium (PharmVar) [1].

In this system:

• The *1 designation historically represents the wild-type, reference, or fully functional allele.
• Numbered star alleles (*2, *3, *4, etc.) represent defined haplotypes composed of one or more single-nucleotide variants, insertions, deletions, or structural alterations.
• An individual's genotype is reported as a diplotype representing the maternal and paternal alleles (e.g., CYP2C19*1/*2).

Assay developers must recognize that a star allele is a haplotype. If an assay tests for only one single-nucleotide variant within a multi-variant haplotype, it cannot definitively call that star allele without appropriate bioinformatic assumptions and explicit reporting disclaimers. Novel variants uncataloged in PharmVar should not be arbitrarily assigned a star allele; they must be reported as variants of uncertain significance (VUS) with an explicit explanation of limitations.

Phenotype Translation: The CYP2D6 Activity Score Model

Raw diplotype calls must be translated into clinical phenotypes: Poor Metabolizer (PM), Intermediate Metabolizer (IM), Normal Metabolizer (NM), or Ultrarapid Metabolizer (UM).

To eliminate discrepancies between clinical guidelines, CPIC and DPWG standardized the CYP2D6 Activity Score (AS) framework:

• Each allele is assigned an activity value: non-functional alleles (*3, *4, *5, *6) receive an AS of 0; decreased-function alleles (*9, *10, *17, *29, *41) receive an AS of 0.25 to 0.5; normal-function alleles (*1, *2) receive an AS of 1.0; and fully functional duplicated alleles (*1xN, *2xN) receive an AS equal to 1.0 multiplied by the copy number.
• The total Activity Score is calculated by summing the values of both alleles:
  • Activity Score 0: Poor Metabolizer (PM)
  • Activity Score 0.25 to 1.0: Intermediate Metabolizer (IM) (Note: An activity score of 1.0 was reclassified from NM to IM under the unified CPIC/DPWG consensus)
  • Activity Score 1.25 to 2.25: Normal Metabolizer (NM)
  • Activity Score > 2.25: Ultrarapid Metabolizer (UM)

Core Pharmacogenes and Variant Selection: AMP Tier 1 vs. Tier 2

A frequent deficiency identified in regulatory and technical audits is improper allele selection. The Association for Molecular Pathology (AMP), together with CAP, publishes formal recommendations defining Tier 1 (must-include minimum panels) and Tier 2 (extended/optional panels) alleles based on clinical impact, well-characterized functional consequence, and minor allele frequency across diverse ancestral populations.

+-------------------------------------------------------------------------------+
|                      AMP Pharmacogenetic Allele Tiers                         |
+-------------------------------------------------------------------------------+
|  TIER 1 (Must-Include Minimum Panel):                                         |
|  - High functional impact demonstrated across multiple clinical studies       |
|  - Known, well-characterized effect on enzymatic activity                     |
|  - Appreciable frequency across at least one major ancestral population      |
|  - Readily available reference materials (e.g., CDC GeT-RM / Coriell)         |
+-------------------------------------------------------------------------------+
|  TIER 2 (Extended / Optional Panel):                                          |
|  - Rare variants (low minor allele frequency globally)                       |
|  - Complex hybrid structural rearrangements                                   |
|  - Developing, emerging, or less definitive functional characterization       |
+-------------------------------------------------------------------------------+

Key Pharmacogenes and Minimum Clinical Targets

• CYP2C19:
  • Tier 1: *2, *3 (no function), and *17 (increased function) [2].
  • Tier 2: *4A, *4B, *5, *6, *7, *8, *9, *10, *35 [2].
  • Clinical Intersection: Antiplatelet therapy (clopidogrel resistance in PM/IM phenotypes necessitates prasugrel or ticagrelor), selective serotonin reuptake inhibitors (sertraline, citalopram, escitalopram), and antifungals (voriconazole).
• CYP2D6:
  • Tier 1: *2, *3, *4, *5 (whole-gene deletion), *6, *7, *8, *9, *10, *17, *29, *41, and gene duplications (*1xN, *2xN, *4xN) [3].
  • Tier 2: Rare SNVs and complex rearrangement hybrids (e.g., *36-*10) [3].
  • Clinical Intersection: Opioid analgesics (codeine and tramadol are contraindicated in PMs due to lack of bioactivation to morphine/O-desmethyltramadol, and in UMs due to severe toxicity risk), tricyclic antidepressants, tamoxifen, and atomoxetine.
• CYP2C9 & VKORC1:
  • Tier 1: CYP2C9 *2, *3, *5, *6, *8, *11; VKORC1 -1639G>A (rs9923231).
  • Clinical Intersection: Warfarin narrow-therapeutic-index dosing, phenytoin, and nonsteroidal anti-inflammatory drugs (celecoxib, ibuprofen).
• DPYD:
  • Target Variants: *2A (c.1905+1G>A), *13 (c.1679T>G), c.2846A>T, and HapB3 (c.1129-5923C>G / c.1236G>A).
  • Clinical Intersection: Fluoropyrimidines (5-fluorouracil, capecitabine). Testing identifies severe dihydropyrimidine dehydrogenase deficiency, preventing life-threatening, treatment-related toxicity via dose reductions or alternative regimens.
• TPMT & NUDT15:
  • Clinical Intersection: Thiopurine therapy (azathioprine, 6-mercaptopurine). Non-functional alleles cause severe, potentially fatal myelosuppression if standard dosing is administered.
• HLA-B Alleles:
  • HLA-B*57:01: Mandatory screening to prevent severe abacavir hypersensitivity reactions.
  • HLA-B*15:02: Mandatory screening in at-risk populations prior to carbamazepine or oxcarbazepine therapy to prevent Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Analytical Validation Framework for PGx Assays

Under CLIA regulations (42 CFR § 493.1253) and CAP molecular pathology accreditation checklists, laboratories establishing a PGx LDT must verify accuracy, precision, analytical specificity, analytical sensitivity (limit of detection), reportable range, reference intervals, and bioinformatics translation pipelines. Pharmacogenomics introduces technical variables rarely encountered in general germline or somatic testing.

Pharmacogenomic Validation Parameters and Technical Solutions

Laboratories navigating test design, assay optimization, or study design can work with specialized advisors through Priestly Consulting's molecular assay development and analytical validation consulting services to ensure technical rigor before initiating clinical testing.

Reference Materials: Utilizing the CDC GeT-RM Catalog

A primary challenge in PGx validation is acquiring clinical specimens with rare variants. Laboratories should not rely solely on banked clinical remnants. The CDC Genetic Testing Reference Materials Coordination Program (GeT-RM), in collaboration with Coriell Cell Repositories, has characterized hundreds of DNA reference samples across major pharmacogenes, resolving ambiguous haplotypes across CYP2D6, CYP2C19, CYP2C9, and CYP2A6. These cell lines provide the sequence-confirmed foundation required for CLIA/CAP method comparison studies and DEX Z-Code dossiers.

Medicare Reimbursement and MolDX Coverage Requirements

Securing Medicare reimbursement for pharmacogenomic testing requires strict adherence to regional Local Coverage Determinations (LCDs) administered by the MolDX program (e.g., Noridian, Palmetto GBA, WPS, CGS) and corresponding billing articles (such as Article A58318) [4].

Single-Gene Coverage vs. Multi-Gene Panel Restrictions

Under MolDX LCD L38294, Medicare covers pharmacogenomics only when testing is medically reasonable and necessary for an active clinical management decision [5].

+-----------------------------------------------------------------------------------------+
|                         MolDX PGx Coverage Decision Framework                           |
+-----------------------------------------------------------------------------------------+
|  SINGLE-GENE TESTING (Covered):                                                         |
|  - Patient is actively taking or being considered for a target drug                     |
|  - Drug-gene pair has an actionable CPIC Level A recommendation                         |
|  - OR drug labeling includes an FDA boxed warning / required dosing intervention        |
|  - Validated clinical necessity documented in the medical record                        |
+-----------------------------------------------------------------------------------------+
|  MULTI-GENE PANELS (Non-Covered Upfront):                                               |
|  - "All-in-one" 20+ gene screening panels are not covered routinely                     |
|  - Population-level or unguided preventive PGx screening is strictly non-covered        |
|  - Every gene billed on a panel must meet individual medical necessity criteria        |
+-----------------------------------------------------------------------------------------+
|  WARFARIN TESTING (Restricted):                                                         |
|  - CYP2C9 and VKORC1 for warfarin are governed by National Coverage Determination 90.1   |
|  - Covered ONLY within prospective Coverage with Evidence Development (CED) trials       |
+-----------------------------------------------------------------------------------------+

Laboratories cannot bill an unbundled multi-gene panel simply because a single drug indication exists for one gene. If a panel is performed, the laboratory must demonstrate that clinical indications were independently satisfied for every gene billed, or absorb the cost of non-covered targets without improper unbundling.

The Bar for Combinatorial Neuropsychiatric Algorithms

Commercial laboratories frequently develop proprietary multi-gene algorithms that assign psychotropic medications to color-coded categories (e.g., "use as directed," "use with caution," or "use with increased monitoring").

MolDX enforces strict evidentiary standards for these combinatorial algorithms:

• The algorithm must demonstrate independent clinical validity and clinical utility beyond the individual gene-drug pairs.
• The proprietary scoring engine must be supported by prospective, peer-reviewed clinical trial data proving that algorithm-guided therapy produces superior clinical outcomes compared to standard management or individual CPIC gene-drug interpretation.
• Non-transparent "black-box" models that obscure raw single-gene contributions face non-coverage determinations.

DEX Z-Codes and Technical Assessment Dossiers

To receive payment under MolDX jurisdictions, a laboratory must:

1. Register the assay within the DEX Diagnostics Exchange.
2. Obtain a unique, test-specific DEX Z-Code identifier.
3. Submit a comprehensive Technical Assessment (TA) dossier.

The TA submission requires complete analytical validation data showing high concordance across AMP Tier 1 variants, clinical validity documentation showing explicit alignment with CPIC guidelines or FDA product labeling, and sample laboratory reports displaying unambiguous diplotype and phenotype translations. Preparing these complex submissions benefits from strategic support through Priestly Consulting's MolDX Technical Assessment service.

Regulatory Frameworks and Prescribing Guidelines

Clinical laboratories must also coordinate conflicting requirements between consensus clinical guidelines and federal regulatory frameworks.

FDA Table of Pharmacogenetic Associations vs. CPIC Guidelines

Laboratories frequently encounter divergence between the FDA Table of Pharmacogenetic Associations and published CPIC guidelines [6]:

• Section 1 (Therapeutic Management Recommendations): Pharmacogenetic associations for which data support specific therapeutic interventions (e.g., dosing adjustments or contraindications) in approved drug labeling [6]. Examples: CYP2C19-clopidogrel, DPYD-fluoropyrimidines, HLA-B*57:01-abacavir.
• Section 2 (Potential Impact on Safety or Response): Gene-drug pairs where data indicate an altered risk of adverse reactions or altered response, though specific clinical management protocols are not explicitly defined in the FDA package insert [6].
• Section 3 (Pharmacokinetic Properties Only): Associations that alter drug blood levels (exposure, AUC) without established alterations in clinical efficacy or safety endpoints [6].

In contrast, CPIC assigns evidence levels (A, B, C, D) based solely on peer-reviewed clinical and functional literature:

• CPIC Level A: Genetic information is recommended to be used to change prescribing of the affected drug; clinical alternatives or dose adjustments are clearly defined.
• CPIC Level B: Alternative prescribing is an option, with moderate evidence.
• CPIC Levels C & D: Insufficient evidence or testing is not clinically actionable.

When constructing clinical decision support language, laboratory reports should prioritize gene-drug pairs supported by CPIC Level A recommendations and FDA Section 1 associations, clearly delineating between regulatory labeling warnings and guideline-recommended dosing titrations.

FDA Oversight of Laboratory-Developed Tests

Laboratories developing PGx LDTs must track the evolving federal oversight framework for laboratory-developed tests. Following the FDA's May 2024 Final Rule regarding in vitro diagnostic products (IVDs), laboratories face phased compliance obligations—including Medical Device Reporting (MDR), corrections and removals, registration and listing, quality system regulations (21 CFR Part 820), and potential premarket review pathways—subject to federal court proceedings.

Regardless of final administrative timelines, laboratories launching PGx LDTs should establish robust design history files (DHFs), document software verification for translation bioinformatics, and maintain full analytical traceabilities to ensure their assays withstand CAP inspections, MolDX Technical Assessments, and federal scrutiny.

How Priestly Consulting Can Help

Priestly Consulting is an independent scientific and healthcare consulting firm serving clinical laboratories, molecular diagnostic developers, biotech companies, and health systems nationwide. The firm provides strategic advisory and documentation support across the entire diagnostic lifecycle, including:

• Assay Strategy & Development: Assisting in the technical design and optimization of targeted genotyping, NGS, and structural variant detection assays for core pharmacogenes.
• Analytical Validation Protocols: Drafting CLIA- and CAP-compliant validation plans, sourcing CDC GeT-RM reference materials, establishing acceptance criteria, and analyzing verification data.
• DEX Z-Codes & MolDX Submissions: Structuring and compiling comprehensive Technical Assessment (TA) evidentiary dossiers to satisfy MolDX LCD L38294 requirements.
• Bioinformatics & CDS Verification: Designing validation frameworks for star-allele diplotype calling and clinical translation software engines aligned with CPIC and PharmVar standards.

Disclaimer: Priestly Consulting is an independent professional advisory firm, not a clinical diagnostic testing laboratory. We do not provide clinical testing services, guarantee specific payer coverage or reimbursement, or guarantee FDA approval or clearance. All regulatory, coding, and reimbursement services represent scientific and strategic documentation support rather than formal legal advice.

To discuss how our consultants can support your laboratory's pharmacogenomics assay validation or MolDX strategy, schedule a consultation with our team.

References

1. Pharmacogene Variation Consortium (PharmVar). Gene and star-allele repository. Available from: https://www.pharmvar.org
2. Pratt VM, Del Tredici AL, Broeckel U, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2018;20(3):269-276. Available from: https://www.amp.org
3. Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2021;23(9):1047-1064. Available from: https://pubmed.ncbi.nlm.nih.gov/34118403/
4. Centers for Medicare & Medicaid Services. Billing and Coding: Pharmacogenomics Testing (Article A58318). Available from: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58318
5. Centers for Medicare & Medicaid Services. Local Coverage Determination: Pharmacogenomics Testing (LCD L38294). Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38294
6. U.S. Food and Drug Administration. Table of Pharmacogenetic Associations. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations